Welcome to our dedicated page for Evofem Biosciences SEC filings (Ticker: EVFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evofem Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evofem Biosciences's regulatory disclosures and financial reporting.
Evofem Biosciences reported Q2 2026 net product sales of $2.6 million, down from $4.8 million a year earlier, and a net loss of $11.0 million, widening from $1.8 million. For the first six months of 2026, net product sales were $3.5 million with a net loss of $16.5 million.
Total assets were $7.5 million at June 30, 2026, versus total liabilities of $90.0 million, and stockholders’ deficit of $87.5 million. The company reported a working capital deficit of $82.5 million and an accumulated deficit of $914.0 million, and stated that these conditions raise substantial doubt about its ability to continue as a going concern.
Evofem continues commercializing PHEXX and, since July 2024, SOLOSEC, and has added ex-U.S. distribution agreements in the Middle East, North Africa, and sub-Saharan Africa. However, it remains highly leveraged, with significant convertible notes and senior subordinated notes and ongoing default disputes on the Baker notes.
HUB Cyber Security Ltd. filed a Schedule 13D reporting beneficial ownership in Evofem Biosciences through senior subordinated convertible notes and purchase rights. Subject to Beneficial Ownership Limitations, HUB may acquire up to 14,709,204 Evofem common shares within 60 days, equal to 9.99% of the class.
The Evofem Notes and Purchase Rights are convertible or exercisable at $0.0154 per share and, without caps or authorized share limits, would cover about 1,268,016,000 shares, approximately 91% of common stock on an as-converted basis. HUB acquired these instruments in June and July 2026 private placements paid entirely in its own ordinary shares and pre-funded warrants, including approximately $49,331,891 for Evofem Notes and June Purchase Rights and $15,200,000 for July Purchase Rights.
HUB characterizes the position as a strategic investment tied to a transformation plan and potential collaboration in women’s health. It also holds a subordinated $706,304 promissory note to fund Evofem suppliers, carrying 12% interest and covenants that restrict major Evofem corporate actions without HUB’s consent.
Evofem Biosciences, Inc. reports that it periodically presents and distributes slide presentations to the investment community to provide updates and summaries of its business. A copy of its current corporate slide presentation, prepared as of July 20, 2026, is being made available on the Investors section of its website.
The same corporate slide deck is furnished as Exhibit 99.1 to a report dated July 20, 2026, together with a Cover Page Interactive Data File as Exhibit 104. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed under the Securities Exchange Act of 1934, and is not incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report is signed on behalf of the company by Chief Executive Officer Saundra Pelletier.
Evofem Biosciences, Inc. incurred new subordinated debt by issuing a promissory note to HUB Cyber Security, Ltd. with an aggregate original principal amount of $706,304. The note bears interest at 12% per annum, compounded monthly, and matures eleven months after July 8, 2026, unless due earlier under its terms.
The note also carries a $2,000 per week Monitoring Fee starting on issuance (approximately $94,000 if outstanding through maturity) and a one-time $14,126 Administration Fee, both payable at maturity. It may be prepaid at any time without premium or penalty, and is a subordinated obligation. Covenants restrict mergers, major asset sales, liquidation, material changes to the business, and certain shareholder payments, and require notice of judgments and events of default. Standard default triggers apply, while defaults alleged by the company’s senior noteholder are expressly excluded as events of default under this note.
Evofem Biosciences, Inc. reported first quarter 2026 results, showing small revenue growth but a return to loss. Net sales were $0.9 million for the three months ended March 31, 2026, slightly above $0.8 million a year earlier, driven by higher pricing and a better gross-to-net mix for PHEXX and SOLOSEC.
Total operating expenses were $5.5 million, leading to a net loss of $5.5 million, or $(0.04) per share, compared with net income attributable to common stockholders of $1.0 million, or $0.01 per basic share, in the prior-year quarter. The balance sheet shows cash and cash equivalents of $1.5 million and a stockholders’ deficit of $77.6 million, highlighting ongoing financial strain.
The company is pursuing growth by commercializing its FDA-approved products PHEXX and SOLOSEC outside the U.S., including a new distribution agreement for SOLOSEC in Sub-Saharan Africa and ongoing regulatory review for both products in the United Arab Emirates. Management reiterates forward-looking statements that emphasize plans for cost reductions, manufacturing efficiencies, and ex-U.S. expansion, while warning about limited cash resources, dependence on new capital or business development transactions, and its ability to continue as a going concern.
Evofem Biosciences reports first-quarter 2026 results showing a small commercial base and significant financial strain. Product sales, net, were $0.9 million, up slightly from $0.8 million a year earlier, while total operating expenses were $5.5 million, leading to an operating loss of $4.6 million and a net loss of $5.5 million attributable to common stockholders, or $(0.04) per share.
Cash, cash equivalents and restricted cash totaled $2.4 million as of March 31, 2026, versus current liabilities of $78.8 million, leaving a working capital deficit of about $72.7 million and a stockholders’ deficit of $77.6 million. Management states that these conditions and dependence on new financing raise substantial doubt about the company’s ability to continue as a going concern.
The company continues commercial activities for non-hormonal contraceptive gel PHEXX and antimicrobial SOLOSEC, expanding through ex-U.S. licensing and distribution agreements in the Middle East, North Africa and sub-Saharan Africa. However, large outstanding convertible and senior notes and extensive potential dilution underscore that the capital structure remains highly leveraged and complex.
Evofem Biosciences has signed a five-year exclusive distributorship agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC (secnidazole) 2 g oral granules in sub-Saharan Africa. Clovis Davis will handle distribution, promotion, marketing, and sales across the Territory.
Local regulatory filings will rely on Evofem’s existing U.S. FDA registration dossier for SOLOSEC, an approved single-dose oral antibiotic for bacterial vaginosis and trichomoniasis. The company highlights significant unmet need, noting that bacterial vaginosis is estimated to affect 25% of women in sub-Saharan Africa, and that in Ethiopia an estimated 10.9 million women may be eligible for SOLOSEC treatment.
Evofem Biosciences, Inc. entered into a fourth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund entities covering previously issued convertible promissory notes. The amendment sets the notes’ maturity as the earlier of six months after April 10, 2026, an Adjuvant‑elected change of control, or any contractual acceleration, and restricts prepayment before six months without Adjuvant’s written consent.
Evofem Biosciences, Inc. reports that it has mutually terminated its License and Supply Agreement with Windtree Therapeutics, Inc., which had made Windtree a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate). The parties entered into a Termination Agreement effective March 13, 2026.
The company states that there are no termination or other fees payable in connection with ending this agreement, helping avoid an immediate financial charge from this change. Certain customary provisions of the original agreement that are meant to survive termination will remain in effect.
Evofem Biosciences reported its fifth consecutive year of net sales growth and a return to profitability for 2025. Full-year net sales were $20.2 million, up from $19.4 million, as higher PHEXX WAC, a better gross-to-net ratio, and a full year of SOLOSEC sales supported growth.
Total operating expenses fell to $16.8 million, a $10.2 million reduction, driving operating income of $3.4 million versus a $7.7 million loss in 2024. Net income attributable to common stockholders was $0.3 million, or $0.00 per basic and diluted share, compared with a $9.0 million net loss, or ($0.11) per share.
In the fourth quarter of 2025, net sales rose to $9.6 million from $7.1 million, a 35% increase, with operating income improving to $3.3 million from a $1.0 million loss. Quarterly net income reached $2.8 million, or $0.02 per basic share and $0.00 per diluted share, versus a $3.0 million net loss a year earlier.